Ver Investigador - - Prisma - Unidad de Bibliometría

David Pozo Pérez

Investiga en

Tipo Año Título Fuente
Editorial2024 Editorial: SARS-CoV-2 in neurodegenerative diseases FRONTIERS IN NEUROSCIENCE
Artículo2024 VEGF expression disparities in brainstem motor neurons of the SOD1G93A ALS model: Correlations with neuronal vulnerability NEUROTHERAPEUTICS
Artículo2023 MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Editorial2022 Editorial: Nanoparticle-mediated signaling rewiring and reprogramming of immune responses FRONTIERS IN IMMUNOLOGY
Artículo2022 Titanium Surface Characteristics Induce the Specific Reprogramming of Toll-like Receptor Signaling in Macrophages INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Nota2021 Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration JOURNAL OF MOLECULAR MEDICINE-JMM
Artículo2021 Distinct responses of human peripheral blood cells to different misfolded protein oligomers IMMUNOLOGY
Artículo2021 The metabesity factor HMG20A potentiates astrocyte survival and reactive astrogliosis preserving neuronal integrity THERANOSTICS
Artículo2020 Modified level of miR-376a is associated with Parkinson's disease JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Resumen congreso2020 Obesity-Induced Astrogliosis Is Regulated by the Diabesity Factor HMG20A DIABETES
Artículo2019 Differential Interactome and Innate Immune Response Activation of Two Structurally Distinct Misfolded Protein Oligomers ACS CHEMICAL NEUROSCIENCE
Artículo2019 Synthesis and Characterization of Elongated-Shaped Silver Nanoparticles as a Biocompatible Anisotropic SERS Probe for Intracellular Imaging: Theoretical Modeling and Experimental Verification NANOMATERIALS
Artículo2018 Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study PLOS ONE
Artículo2018 Immunization with alpha-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model GLIA
Artículo2018 LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus NATURE COMMUNICATIONS
Artículo2018 Tissue-Specific Phenotype and Activation of iNKT Cells in Morbidly Obese Subjects: Interaction with Adipocytes and Effect of Bariatric Surgery OBESITY SURGERY
Artículo2017 Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis Advances in experimental medicine and biology
Artículo2017 Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia FASEB JOURNAL
Capítulo2017 Update on nanoparticle-mediated immune mechanisms for dendritic cell-based targeted immunity and cancer NANOMEDICINE IN CANCER
Artículo2016 Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the alpha-synuclein-elicited immune response FASEB JOURNAL
Revisión2016 Iron oxide nanoparticles as magnetic relaxation switching (MRSw) sensors: Current applications in nanomedicine NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Revisión2016 The 'Omics' of Amyotrophic Lateral Sclerosis TRENDS IN MOLECULAR MEDICINE
Resumen congreso2016 The LRH1 Agonist BL001 Simultaneously Targets Immune and Islet Cells to Repress Type 1 Diabetes DIABETES
Artículo2016 Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2 SCIENCE SIGNALING
Artículo2015 Betalactam antibiotics affect human dendritic cells maturation through MAPK/NF-kB systems. Role in allergic reactions to drugs TOXICOLOGY AND APPLIED PHARMACOLOGY
Artículo2015 Long-circulating PEGylated manganese ferrite nanoparticles for MRI-based molecular imaging NANOSCALE
Artículo2015 Polysaccharide Colloids as Smart Vehicles in Cancer Therapy CURRENT PHARMACEUTICAL DESIGN
Artículo2015 Synthesis of 1D-glyconanomaterials by a hybrid noncovalent-covalent functionalization of single wall carbon nanotubes: a study of their selective interactions with lectins and with live cells NANOSCALE
Revisión2015 Vasoactive Intestinal Peptide (lVIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery PROTEIN AND PEPTIDE NANOPARTICLES FOR DRUG DELIVERY
Artículo2014 Chaperoned amyloid proteins for immune manipulation: alpha-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype IMMUNITY INFLAMMATION AND DISEASE
Resumen congreso2013 Invariant natural killer T cells could influence B cells changes in Dermatophagoides pteronyssinus immunotherapy ALLERGY
Resumen congreso2013 Invariant Natural Killer T Cells Populations in Peripheral Blood From Allergic Rhinitis Patients: Regulatory or Pathologic Role? JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Resumen congreso2013 Participation of invariant natural killer T cells in allergen-specific immunotherapy: regulatory or pathologic role? ALLERGY
Artículo2013 Preconditioning of Microglia by alpha-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation PLOS ONE
Resumen congreso2013 The LRH-1 agonist BL001 improves human islet survival and blunts development of hyperglycaemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes DIABETOLOGIA
Resumen congreso2012 Engineered nanoparticles for improved vasoactive intestinal peptide (VIP) applications JOURNAL OF MOLECULAR NEUROSCIENCE
Resumen congreso2012 Funcionalización de nanopartículas con el neuropéptido VIP como estrategia de mejora de su potencial de aplicación en biomedicina Biosaia
Resumen congreso2012 Improved drugability of vasoactive intestinal peptide (VIP) by nanotechnology for therapeutic selective targeting and immunomodulation JOURNAL OF NEUROIMMUNOLOGY
Resumen congreso2012 Invariant natural killer T-cells frequency in peripheral blood from allergic patients to house dust mite is higher than in tolerant controls ALLERGY
Resumen congreso2012 Involvement of wild-type alpha-synuclein and Parkinson's disease mutants in human monocyte-derived dendritic maturation MOLECULAR IMMUNOLOGY
Resumen congreso2012 Multicentre clinical trial phase I/II randomised, placebo-controlled study to evaluate safety and feasibility of therapy with two different doses of autologous mesenchymal stem cells in patients with SPMS who do not respond to treatment MULTIPLE SCLEROSIS
Artículo2012 Nanoporous silica microparticle interaction with toll-like receptor agonists in macrophages ACTA BIOMATERIALIA
Resumen congreso2012 Preconditioning of microglia with Parkinson-linked alpha-synuclein affects the response induced by Toll-like receptor (TLR) stimulation JOURNAL OF NEUROIMMUNOLOGY
Artículo2011 Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications Recent Patents on Nanomedicine
Artículo2010 Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimer's Disease JOURNAL OF MOLECULAR NEUROSCIENCE
Resumen congreso2010 Engineering of silver-protected VIP nanoparticles: chemical synthesis and functional characterization JOURNAL OF MOLECULAR NEUROSCIENCE
Artículo2010 Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants PLOS ONE
Resumen congreso2010 Glial innate immunity generated by non-aggregated alpha-synuclein: Differences between wild-type and Parkinson's disease-linked mutants JOURNAL OF NEUROIMMUNOLOGY
Revisión2010 Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Artículo2010 Silver nanoparticles interactions with the immune system: implications for health and disease SILVER NANOPARTICLES
Editorial2010 SILVER NANOPARTICLES Preface SILVER NANOPARTICLES
Artículo2010 Silver nanoparticles: sensing and imaging applications SILVER NANOPARTICLES
Artículo2010 The Occurrence of the Biogenic Amine Melatonin in Olive Oil: Implications in Health and Disease Prevention Olives and olive oil in health and disease prevention (Second Edition)
Resumen congreso2010 Vasoactive intestinal peptide and its role in inflammatory diseases and self/non-self discrimination JOURNAL OF MOLECULAR NEUROSCIENCE
Artículo2009 Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip EMBO JOURNAL
Artículo2009 Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles NANOMEDICINE
Artículo2009 Induction of Alloantigen-Specific Human T Regulatory Cells by Vasoactive Intestinal Peptide JOURNAL OF IMMUNOLOGY
Resumen congreso2009 New action mechanisms for ADNP/NAP as immunomodulatory players FEBS JOURNAL
Artículo2009 Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Revisión2008 Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Editorial2008 Immune-based disorders: the challenges for translational immunology JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Artículo2008 Tiopronin monolayer-protected silver nanoparticles modulate IL-6 secretion mediated by Toll-like receptor ligands NANOMEDICINE
Artículo2007 Melatonin is a phytochemical in olive oil FOOD CHEMISTRY
Resumen congreso2007 New cellular and humural immune-targeted mechanisms by VIP/ADNP neuropeptides with prospective therapeutic uses FEBS JOURNAL
Artículo2007 Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders PEPTIDES
Artículo2006 CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase JOURNAL OF IMMUNOLOGY
Artículo2006 Histomorphogenesis and immunohistochemical study of the bovine pineal gland (Bos taurus) during prenatal development (160 days of gestation to birth) HISTOLOGY AND HISTOPATHOLOGY
Letter2006 Impairment of the melatonin rhythm in children with Sanfilippo syndrome JOURNAL OF PINEAL RESEARCH
Artículo2006 NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Artículo2006 Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Revisión2006 The modulatory role of melatonin on immune responsiveness CURRENT OPINION IN INVESTIGATIONAL DRUGS
Resumen congreso2006 The NAP peptide derived from the activity-dependent neuroprotective protein (ADNP) is a new immunomodulator with therapeutic effects in the adoptive transfer model of experimental allergic encephalomyelitis JOURNAL OF IMMUNOLOGY
Artículo2006 Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis - Down-regulation of inflammatory and autoimmune responses AMERICAN JOURNAL OF PATHOLOGY
Artículo2006 VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Resumen congreso2005 NAP, a peptide derived from activity-dependent neuroprotective protein (ADNP), is a potent modulator innate and adaptive immunity: Prevention of autoimmune experimental encephalomyelitis REGULATORY PEPTIDES
Artículo2005 The use of melatonin as a vaccine agent VACCINE
Artículo2005 Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Resumen congreso2005 VIP gene delivery protects non-obese diabetic (NOD/LtJ) mice from cyclophosphamide-accelerated diabetes REGULATORY PEPTIDES
Artículo2004 Effects of celecoxib on acid-challenged gastric mucosa of rats: Comparison with metamizol and piroxicam DIGESTIVE DISEASES AND SCIENCES
Artículo2004 mRNA expression of nuclear receptor RZR/ROR alpha, melatonin membrane receptor MT1, and hydroxindole-O-methyltransferase in different populations of human immune cells JOURNAL OF PINEAL RESEARCH
Artículo2004 RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line CANCER LETTERS
Artículo2004 The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB JOURNAL
Revisión2004 The significance of vasoactive intestinal peptide in immunomodulation PHARMACOLOGICAL REVIEWS
Artículo2003 Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro JOURNAL OF PINEAL RESEARCH
Revisión2003 VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools TRENDS IN MOLECULAR MEDICINE
Artículo2002 Mechanisms involved in protection afforded by L-arginine in Ibuprofen-induced gastric damage - Role of nitric oxide and prostaglandins DIGESTIVE DISEASES AND SCIENCES
Artículo2002 Melatonin prevents focal rat cerebellum injury as assessed by induction of heat shock protein (HO-1) following subarachnoid injections of lysed blood Neuroscience Letters
Artículo2002 Oxidative stress induced by phenylketonuria in the rat: Prevention by melatonin, vitamin E, and vitamin C JOURNAL OF NEUROSCIENCE RESEARCH
Artículo2002 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1 alpha production and mRNA expression CYTOKINE
Artículo2000 Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines JOURNAL OF PINEAL RESEARCH
Corrección2000 Erratum: Immunobiology of vasoactive intestinal peptid (VIP) (Immunology Today (2000) vol. 21(1), (7-11)) Immunology Today
Artículo2000 Functional and molecular characterization of VIP receptor-effector system in rat developing immunocompetent cells: G protein involvement JOURNAL OF NEUROIMMUNOLOGY
Artículo2000 Identification of G-protein coupled receptor subunits in normal human dental pulp JOURNAL OF ENDODONTICS
Artículo2000 Immunobiology of vasoactive intestinal peptide (VIP) Immunology Today
Corrección2000 Immunobiology of vasoactive intestinal peptide (VIP) (vol 21, pg 7, 2000) Immunology Today
Artículo2000 Involvement of nuclear receptors in the enhanced IL-2 production by melatonin in Jurkat cells ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Ponencia2000 Nitric oxide mechanisms in protection afforded by L-arginine in ibuprofen induced gastric toxicity. GASTROENTEROLOGY
Artículo2000 Nuclear receptors are involved in the enhanced IL-6 production by melatonin in U937 cells Biological Signals and Receptors
Artículo2000 Postnatal development of vasoactive intestinal peptide receptor-effector system in rat immunocompetent cells ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Artículo1999 Characterization of membrane melatonin receptor in mouse peritoneal macrophages: Inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein JOURNAL OF NEUROIMMUNOLOGY
Artículo1999 Melatonin activates Th1 lymphocytes by increasing IL-12 production LIFE SCIENCES
Artículo1999 Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats FASEB JOURNAL
Artículo1999 Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase- activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6 JOURNAL OF IMMUNOLOGY
Artículo1999 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies JOURNAL OF IMMUNOLOGY
Ponencia1998 Effect of chlorhexidine digluconate on substrate adherence capacity of macrophages. JOURNAL OF DENTAL RESEARCH
Resumen congreso1998 Protein expression of heterotrimeric G-protein subunits in normal human dental pulp. JOURNAL OF DENTAL RESEARCH
Ponencia1998 The bleaching agent Amosan (R) (sodium perborate) inhibits macrophage adhesion. JOURNAL OF DENTAL RESEARCH
Ponencia1998 The bleaching agent amosanr (sodium perborate) inhibits macrophage adhesion JOURNAL OF DENTAL RESEARCH
Artículo1998 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages Journal of leukocyte biology
Artículo1998 VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies JOURNAL OF NEUROIMMUNOLOGY
Ponencia1997 Characterization of gene expression of the membrane melatonin receptor in rat thymus and spleen PINEAL UPDATE
Artículo1997 Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages EUROPEAN JOURNAL OF PHARMACOLOGY
Artículo1997 Differential adrenergic regulation of rat pineal cyclic AMP production and N-acetyltransferase activity during postnatal development: involvement of G(alpha S) and G(alpha i1-2) proteins JOURNAL OF ENDOCRINOLOGY
Revisión1997 Expression of membrane melatonin receptor mRNA in rat thymus and spleen THERAPEUTIC POTENTIAL OF MELATONIN
Artículo1997 Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen FASEB JOURNAL
Artículo1997 Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Artículo1997 Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin JOURNAL OF CELLULAR BIOCHEMISTRY
Capítulo1997 Mechanisms of action of melatonin on the human immune system: membrane versus nuclear receptors THERAPEUTIC POTENTIAL OF MELATONIN
Artículo1997 Signal Transduction for Melatonin in Human Lymphocytes: Involvement of a Pertussis Toxin-Sensitive G Protein JOURNAL OF IMMUNOLOGY
Artículo1996 Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Artículo1996 Characterization of binding sites for beta-adrenergic agonists and vasoactive intestinal peptide in the rat harderian gland MICROSCOPY RESEARCH AND TECHNIQUE
Artículo1996 Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages REGULATORY PEPTIDES
Artículo1996 Expression of vasoactive intestinal peptide binding sites in rat peritoneal macrophages is stimulated by inflammatory stimulus JOURNAL OF NEUROIMMUNOLOGY
Revisión1996 Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems ADVANCES IN NEUROIMMUNOLOGY
Artículo1996 Melatonin reduces nitric oxide synthase activity in rat hypothalamus JOURNAL OF PINEAL RESEARCH
Artículo1996 Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells IMMUNOPHARMACOLOGY
Artículo1995 HOMOLOGOUS REGULATION OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) RECEPTORS ON RAT PERITONEAL-MACROPHAGES PEPTIDES
Artículo1995 Immunomodulatory role of melatonin - specific binding-sites in human and rodent lymphoid-cells JOURNAL OF PINEAL RESEARCH
Artículo1995 SPECIFIC BINDING OF 2-[I-125]IODOMELATONIN BY RAT SPLENOCYTES - CHARACTERIZATION AND ITS ROLE ON REGULATION OF CYCLIC-AMP PRODUCTION JOURNAL OF NEUROIMMUNOLOGY
Artículo1995 VIP RECEPTOR-EFFECTOR SYSTEM IN RAT HARDERIAN-GLAND AND ITS COUPLING TO ACTIVATION OF TYPE-II THYROXINE 5'-DEIODINASE PEPTIDES
Artículo1994 Peptide-t from human-immunodeficiency-virus does not interact with vip receptor-effector system in immunocompetent cells of rat and mouse BIOSCIENCE REPORTS
Letter1994 Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum LIFE SCIENCES

Tesis dirigidas/tutorizadas:12
Fecha lectura Título Rol
13/05/2024 Mecanismos modulatorios de MOK en la regulación de la respuesta inflamatoria de la microglía en ELA Tutor/a, Director/a
16/02/2023 Impacto de la infección por el VIH en el desarrollo de la enfermedad hepática grasa y análisis de los condicionantes genéticos involucrados en la población infectada Tutor/a
10/06/2022 Hidrogeles supramoleculares y nanosistemas funcionales basados en carbohidratos para diferentes aplicaciones biomédicas Tutor/a
22/05/2019 NOVEL MOLECULAR MECHANISMS AND SIGNALING PATHWAYS OF MICROGLIAL RESPONSES IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) Director/a, Tutor/a
22/05/2017 ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; THERAPEUTIC APPROACHES OF ITS MODULATION BY MOLECULAR CHAPERONES Director/a
03/06/2016 ESCLEROSIS LATERAL AMIOTRÓFICA: INVESTIGACIONES EN EL MODELO SOD1G93A Y CORRELACIONES DE INTERÉS CLÍNICO Director/a
25/06/2015 UTILIZACIÓN DE NANOPARTÍCULAS DE ORO COMO HERRAMIENTA REGULADORA DE LA ACTIVIDAD TREG/ITE EN ESCLEROSIS MÚLTIPLE Director/a
08/01/2014 NANOTECHNOLOGY APPROACHES FOR IMPROVOVED VASOACTIVE INTESTINAL PEPTIDE BASED-DRUG DELIVERY SYSTEMS Director/a
08/10/2013 EFECTOS INMUNOMODULADORES DEL PÉPTIDO BIOACTIVO NAP Y EVALUACIÓN TERAPÉUTICA EN LA INFLAMACIÓN Tutor/a, Director/a
03/05/2012 PAPEL INMUNOMODULADOR DEL PÉPTIDO NEUROPROTECTOR NAP DERIVADO DE LA PROTEÍNA ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (ADNP) Director/a
03/12/2010 Valoración cualitativa y cuantitativa del DNA circulante en suero como marcador tumoral en el cáncer de pulmón Director/a, Tutor/a
17/12/2003 REGULACIÓN POR MELATONINA DE LA ACTIVIDAD Y EXPRESIÓN DE LA TELOMERASA EN CÉLULAS TUMORALES HUMANAS MCF-7 Director/a

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
28/11/2003 28/11/2006 Responsable Inmunoregulación de las células Natural Killer T (NK-T) por VIP: análisis funcional, mecanismos de acción y efecto sobre la patogénesis de la diabetes tipo 1 como modelo de enfermedad autoinmune Th1 (PI030359) Ministerio de Sanidad y Consumo (Instituto de Salud Carlos III) (Nacional)
23/12/2005 23/12/2008 Responsable Efectos inmunomoduladores del péptido bioactivo NAP, mecanismos de acción y evaluación terapéutica en la inflamación crónica: implicaciones en la esclerosis múltiple y la enfermedad de Crohn (PI052056) Ministerio de Sanidad y Consumo (Instituto de Salud Carlos III) (Nacional)
17/10/2006 30/12/2009 Responsable Efecto del péptido biactivo NAP en un modelo experimental de artritis reumatoide: regulación de los componentes inflamatorios y autoinmunes y estudio prospectivo terapeútico (PI061641) Ministerio de Sanidad y Consumo (Instituto de Salud Carlos III) (Nacional)
13/04/2007 12/04/2010 Investigador/a Estudios inmunobiológicos y de degeneración neuronal parkinsoniana tras la inactivación génica de la biosíntesis (P06-CTS-01604) Junta de Andalucía (Plan Andaluz de Investigación) (Autonómico)
26/03/2013 31/05/2018 Responsable Desarrollo Preclínico del Eje de Neuropéptidos VIP/Adnp como Agentes Modificadores de Actividad Biológica de Células Madres de Médula Ósea en el Modelo Experimental de Esclerosis Lateral Amiotrófica (P11-CTS-8161) Junta de Andalucía - Consejería de Innovación, Ciencia y Empresas (Autonómico)
01/01/2015 31/12/2017 Responsable Sistemas nanoestructurados direccionados por el péptido intesinal vasoactivo (VIP) como alternativas para la detección y tratamiento de cáncer de próstata: caracterización preclínica (PI14/01600) Ministerio de Economía y Competitividad (Instituto de Carlos III) (Nacional)
01/01/2010 31/12/2012 Responsable Estudio de la capacidad inmunoreguladora del péptido intestinal vasoactivo (VIP) sobre células madre derivadas de tejido adiposo (CMDA) en el modelo preclínico de esclerosis múltiple (PS09/02252) Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III) (Nacional)
03/06/2006 02/06/2008 Investigador/a Evaluación y caracterización funcional del potencial adyuvante de la melatonina en la vacunación contra clostridium y chalmydophila en oveja (PTR1995-1011-OP) Ministerio de Educación y Ciencia (Nacional)
01/01/2019 31/12/2022 Responsable Caracterización Funcional e Intervención de una Nueva Ruta de Señalización de la Neuroinflamación Mediada por Microglia en Esclerosis Lateral Amiotrófica (Ela) (RTI2018-098432-B-I00) Ministerio de Ciencia, Innovación y Universidades (Nacional)
05/10/2021 31/03/2023 Investigador/a Mecanismos moleculares de una proteína de la familia BET en la respuesta neuroinflamatoria asociada a proteinopatías neurodegenerativas (P20_01097) Consejería de Economía, Conocimiento, Empresas y Universidad (Autonómico)
01/11/2000 30/04/2002 Investigador/a Caracterización de los efectos antiinflamatorios de la Neurohormona melatonina: Estudio in vitro e in vivo. (PTR-1995-0451-OP) Ministerio de Educación, Cultura y Deporte (Nacional)
01/02/2020 31/01/2022 Investigador/a Caracterización funcional y de los mecanismos de acción mediados por MOK en la neuroinflamación asociada a proteinopatías neurodegenerativas: Esclerosis Lateral Amiotrófica (ELA) y Enfermedad de Parkinson (US-1265227) Junta de Andalucía (Consejería de Economía y Conocimiento) (Autonómico)
01/12/2002 01/12/2005 Investigador/a Neuroinmunoregulación de las células cebadas: mecanismos de acción y efectos biológicos de la melatonina y el VIP (BFI2002-03544) Ministerio de Ciencia y Tecnología (Nacional)
19/12/2005 19/12/2006 Responsable Estudio de los efectos del gen ADNP y del péptido bioactivo NAP en patologías con un componente inmunitario (SUVB. I.C.A.I.) Universidad Pontificia Comillas (ICAI) (Autonómico)
20/01/2009 20/01/2012 Responsable Síntesis y caracterización biológica de nanopartículas funcionalizadas con el péptido intestinal vasoactivo (Vip) como plataforma de medicamentos innovadores en cáncer de próstata: efectos inmunoreguladores y antitumorales (PI-0068/2008) Junta de Andalucía (Consejería de Salud) (Autonómico)
15/03/2011 30/06/2015 Responsable Nanotecnología como Plataforma de Desarrollo de Inmunoterapias Mediadas por Nanoparticulas Funcionalizadas con Péptido Intestinal Vasoactivo (VIP) en enfermedades inflamatorias Yautoinmunes: Proyecto Nanovip (P10-CTS-6928) Junta de Andalucía - Consejería de Innovación, Ciencia y Empresas (Autonómico)
01/01/2015 31/12/2018 Investigador/a Desarrollo de una terapia para el tratamiento de variantes genéticas de alfa-sinucleína en la enfermedad de parkinson (RTC-2015-3309-1) Ministerio de Economía y Competitividad (Nacional)
03/04/2019 30/04/2024 Investigador/a Caracterización funcional y de los mecanismos de acción mediados por la kinasa de señalización MOK en la neuroinflamación asociada a la Esclerosis Lateral Amiotrófica (ELA) (2019/FARECES/CROODVELT) Fundación Ramón Areces (Nacional)
03/02/2010 03/02/2013 Investigador/a Nuevas Terapias Antiparasitarias: Uso de Neuropéptidos Endógenos (P09-CTS-4705) Junta de Andalucía - Consejería de Innovación, Ciencia y Empresas (Autonómico)

Contratos

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
30/06/2007 30/06/2008 Responsable Construcción de genotecas de anticuerpos de cadena sencilla (SI-079/07) Newbiotechnic, S.A. (Desconocido)
24/09/2007 24/09/2008 Responsable Diseño e implantación de programas y proyectos de innovación e investigación biomédica del Sistema Sanitario Público de Andalucia (0014/0013) Fundación Progreso y Salud (Desconocido)
01/10/2009 31/12/2009 Responsable Realización de pruebas de concepto para el estudio de la actividad inmunomoduladora del condroítin sulfato. (0541/0013) BIOIBÉRICA, S.A. (Desconocido)
30/06/2008 30/06/2009 Responsable Construcción de genotecas de anticuerpos de cadena sencilla (SI-008/09) Newbiotechnic, S.A. (Desconocido)
01/11/2016 30/09/2017 Responsable VIPCURE: The development of a Therapeutic Viral Vector Vaccine for the treatment of Amyotrophic Lateral Sclerosis (2901/0013) Amarna Therapeutics, S.L. (Desconocido)
30/06/2006 30/06/2007 Responsable Construcción de genotecas de anticuerpos de cadena sencilla (SI-003/07) Newbiotechnic, S.A. (Desconocido)
30/06/2009 30/06/2010 Responsable Biomarcadores. Desarrollo y aplicaciones en agroalimentación y sanidad. (Prórroga) (SI-001/09) Newbiotechnic, S.A. (Desconocido)
01/01/2010 31/12/2010 Responsable Diseño e implantación de Programas de I+D+I estratégicos en Terapia Génica, Celular y Nanomedicina. Área Desarrollo de la Producción Científica. Fundación Pública Andaluza Progreso y Salud. Consejería de Salud. Junta de Andalucía. (0669/0013) Fundación Progreso y Salud (Desconocido)
01/01/2014 31/12/2017 Responsable Towards a therapeutic vaccine for Amyotrophic lateral sclerosis: ALSVac (2106/0013) Amarna Therapeutics, S.L. (Desconocido)

Ayudas

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
06/03/2006 06/08/2006 Responsable Estudio prospectivo del uso terapéutico como inmunomodulador del péptido bioactivo NAP (OTRI/05-FP02) Universidad de Sevilla(Oficina de Transferencia de Resultados de Investigación) (Local)
15/11/2006 17/11/2006 Responsable Salud y calidad de vida ¿Que podemos aprender de nuestros científicos) I Jornadas Andaluzas de Ciencias y Sociedad 2006 desde la Universidad de Sevilla (PP2005-01-23) Universidad de Sevilla (Local)
01/01/2008 31/12/2008 Responsable Are there natural autoepitope-mimiching melecules with cytotoxic activity, capable of preventing autoimmune disease? A basic biological question with strong biotechnological implications (SAF2007-29418-E) Ministerio de Educación y Ciencia (Nacional)